$VRTX News Article - Vertex Announces European Commission Approval for SYMKEVI (tezacaftor/ivacaftor) With KALYDECO (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years https://marketwirenews.com/news-releases/vert...07052.html
(0)
(0)
Vertex Pharmaceuticals Inc. (VRTX) Stock Research Links